Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Revenue projections:

Revenue projections for GLENMARK
Revenue projections for GLENMARK

Revenues for GLENMARK are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.55800
forwardPE 25.08557
debtToEquity 27.94300
earningsGrowth 0.00000
revenueGrowth -0.16100
grossMargins 0.67598
operatingMargins 0.13694
trailingEps 37.15000
forwardEps 42.48000

GLENMARK's current ratio being 1.558 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, GLENMARK can easily cover its immediate liabilities, reflecting solid financial health.
Glenmark Pharmaceuticals Limited's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
Glenmark Pharmaceuticals Limited's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests Glenmark Pharmaceuticals Limited maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
Glenmark Pharmaceuticals Limited's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.
GLENMARK's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that GLENMARK is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for GLENMARK
Price projections for GLENMARK

The steady upward revision of GLENMARK's price projections indicates growing confidence in the company's future. Analysts are increasingly optimistic about GLENMARK's potential to deliver strong results and increased market value.

Recommendation changes over time:

Recommendations trend for GLENMARK
Recommendations trend for GLENMARK


A recent buy bias from analysts toward GLENMARK may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that GLENMARK might be an appealing option for those looking to grow their wealth through stock market investments.